DPP-4 inhibitors: Difference between revisions
(Created page with "=== '''Introduction''' === Dipeptidyl Peptidase-4 Inhibitors (gliptans) are oral hypoglycemics that block DPP-4. This leads to an increase in the activity of incretins, which...") |
No edit summary |
||
| Line 1: | Line 1: | ||
=== '''Introduction''' === | === '''Introduction''' === | ||
Dipeptidyl Peptidase-4 Inhibitors (gliptans) are oral hypoglycemics that block DPP-4. This leads to an increase in the activity of incretins, which inhibit glucagon release, which in turn increase insulin secretion and slow gastric emptying, ultimately decreasing blood glucose levels. | Dipeptidyl Peptidase-4 Inhibitors (gliptans) are a class of oral hypoglycemics that block DPP-4. This leads to an increase in the activity of incretins, which inhibit glucagon release, which in turn increase insulin secretion and slow gastric emptying, ultimately decreasing blood glucose levels. These drugs are commonly used in the treatment of type 2 diabetes. | ||
=== '''FDA Approved DPP-4 Inhibitors''' === | |||
{| class="wikitable" | |||
|- | |||
! Brand Name !! Active Ingredient(s) | |||
|- | |||
| Januvia || sitagliptin | |||
|- | |||
| Janumet || sitagliptin, metformin | |||
|- | |||
| Janumet XR || sitagliptin, metformin ER | |||
|- | |||
| Onglyza || saxagliptin | |||
|- | |||
| Kombiglyze XR || saxagliptin, metformin ER | |||
|- | |||
| Tradjenta || linagliptin | |||
|- | |||
| Glyxambi || linagliptin, empagliflozin | |||
|- | |||
| Jentadueto || linagiptin, metformin | |||
|- | |||
| Nesina || alogliptin | |||
|- | |||
| Kazano || alogliptin, metformin | |||
|- | |||
| Oseni || alogliptin, pioglitazone | |||
|} | |||
=== '''Mechanism of Action''' === | === '''Mechanism of Action''' === | ||
| Line 9: | Line 37: | ||
=== '''References''' === | === '''References''' === | ||
US Food and Drug Administration. "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain." FDA, 6/23/2016. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm | |||
Revision as of 07:15, 30 December 2016
Introduction
Dipeptidyl Peptidase-4 Inhibitors (gliptans) are a class of oral hypoglycemics that block DPP-4. This leads to an increase in the activity of incretins, which inhibit glucagon release, which in turn increase insulin secretion and slow gastric emptying, ultimately decreasing blood glucose levels. These drugs are commonly used in the treatment of type 2 diabetes.
FDA Approved DPP-4 Inhibitors
| Brand Name | Active Ingredient(s) |
|---|---|
| Januvia | sitagliptin |
| Janumet | sitagliptin, metformin |
| Janumet XR | sitagliptin, metformin ER |
| Onglyza | saxagliptin |
| Kombiglyze XR | saxagliptin, metformin ER |
| Tradjenta | linagliptin |
| Glyxambi | linagliptin, empagliflozin |
| Jentadueto | linagiptin, metformin |
| Nesina | alogliptin |
| Kazano | alogliptin, metformin |
| Oseni | alogliptin, pioglitazone |
Mechanism of Action
Indications
Adverse Effects
References
US Food and Drug Administration. "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain." FDA, 6/23/2016. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm